Jiangxi Biology IPO: Key Product Enjoys Global Market Leadership; Pipeline Lends Visibility
Jiangxi Biology has launched HK IPO consisting of 36M H shares at HK$9.33–13.06 per share to fund R&D and construction and expansion of new...
126 Views
Primer: Jiangxi Institute of Biological Products (JIBP HK) - Apr 2026
Dominant Market Leader in Tetanus Antitoxin (TAT): Jiangxi Institute of Biological Products (JIBP) is the largest provider of human tetanus...
117 Views
APAC Healthcare Weekly (July 5) – CSPC, Abbisko, Insilico, Takeda, Nippon Shinyaku, Otsuka, CSL
CSPC, Insilico, and Abiisko inked outlicensing deals with international companies. Nippon Shinyaku inlicenses DMD drug candidate. EMA recommends to...
305 Views
Pre-IPO Jiangxi Institute of Biological Products-Concerns Behind the Strong Growth and Profitability
Jiangxi Institute of Biological Products leads in Human TAT with strong profitability, but future growth may slow. Technical barriers/global...
431 Views